Canine eosinophilic skin diseases (dermatoses) are uncommon heterogeneous disorders of different clinical phenotypes characterized by the development of acute skin lesions.\textsuperscript{1,2} Eosinophils have many roles in the homeostasis of the immune system and are considered the effector cells involved primarily in the defense against parasites and allergic inflammation.\textsuperscript{1} Dermatosis with eosinophilic infiltration has, rarely, been reported in association with parasites such as \textit{Pelodera} species and hookworms in dogs.\textsuperscript{3} More reports describe acute “sterile” canine eosinophilic dermatoses, such as acute eosinophilic dermatitis with edema and eosinophilic folliculitis/furunculosis.\textsuperscript{1,4} Although the etiology of sterile eosinophilic dermatoses is unknown, a type I hypersensitivity or an adverse drug reaction is considered to play a possible role.\textsuperscript{1,4} These eosinophilic dermatoses tend to progress rapidly, and patients are frequently presented through emergency services. Therefore, clinicians should be familiar with eosinophilic folliculitis/furunculosis to establish an accurate diagnosis and initiate early successful therapy.

**HISTORY**

A 5.5-year-old, 29-kg (64-lb), female spayed German shorthaired pointer was presented during the summer with a 4-day history of an acute, pruritic cutaneous eruption and hemorrhagic exudate confined to the bridge of the nose. The history of fever, clinical features (e.g., peracute development, lesion localization, cytology findings showing numerous eosinophils and no bacteria) and histopathologic findings were consistent with canine eosinophilic folliculitis/furunculosis. Oral immunomodulatory prednisone intervention resulted in significant improvement in the dog’s condition and resolution of skin lesions over the following 24 days. Clinicians should be familiar with the disease to establish an accurate diagnosis and initiate early successful therapy.
eruption and hemorrhagic exudate confined to the bridge of the nose. The sudden change in the dog’s health was not associated with any vaccine or drug administration; the patient was previously healthy. The owner reported that, initially, the lesions consisted of edema and small bumps, but they had progressively increased in size and worsened in sensitivity and discomfort over 4 days. The patient received regular monthly oral afoxolaner for tick and flea prevention. Amoxicillin–clavulanic acid (375 mg q12h) had been

Take-Home Points

- Canine eosinophilic skin diseases (dermatoses) are uncommon heterogeneous disorders of different clinical phenotypes characterized by the development of acute skin lesions.
- Acute “sterile” eosinophilic dermatoses in dogs, such as acute eosinophilic dermatitis with edema and eosinophilic folliculitis/furunculosis, have recently been frequently reported in the literature. These “sterile” eosinophilic dermatoses tend to progress quickly, with patients frequently presented through emergency services.
- This case report details the diagnostic approach and successful therapy of a canine patient diagnosed with eosinophilic folliculitis/furunculosis.
- Canine eosinophilic folliculitis/furunculosis is diagnosed based on history, characteristic clinical signs, cytology, and skin biopsies.
- Oral systemic glucocorticoids have been the mainstay of therapy for canine eosinophilic folliculitis/furunculosis cases; effective dosages for prednisone/prednisolone of 1–2 mg/kg have been recommended in previous publications.
- Clinicians should be familiar with the disease to establish an accurate diagnosis and initiate early successful therapy.

FIGURE 1. Eosinophilic folliculitis/furunculosis in a 5.5-year-old German shorthaired pointer. (A) Erythematous, eroded to ulcerated plaques with hemorrhagic exudate confined to the cranial part of the bridge of the nose. (B) Small satellite skin lesions characterized by several multifocal erosions to ulcers with crusting (arrow). (C) Dorsal view.
initiated a day before referral by the primary veterinarian; however, there was no improvement in clinical signs.

**PRESENTATION AND DIAGNOSIS**

At the time of presentation, the physical examination revealed no abnormalities apart from the dermatosis. The patient was alert and responsive; lymphadenopathy was not observed. Skin lesions consisted of 2 erythematous, eroded to ulcerated plaques with hemorrhagic exudate confined to the cranial part of the bridge of the nose (**FIGURE 1**); these lesions were pruritic and painful on palpation. Small satellite skin lesions surrounded the plaques and were characterized by several multifocal erosions to ulcers with crusting (**FIGURE 1B**). There was no involvement of mucous membranes, mucocutaneous junctions, or other body sites. The results of a complete blood count and serum biochemical profile were unremarkable. The differential diagnoses included eosinophilic folliculitis/furunculosis, staphylococcal nasal folliculitis/furunculosis, demodicosis, thermal burn, solar dermatitis, dermatophytosis, and juvenile cellulitis.

Microscopic examination of skin scrapings and hair plucks failed to detect ectoparasites or dermatophytes. Cytologic examination of eroded plaques using Diff-Quik staining showed intense cellularity with numerous eosinophils, occasional macrophages, and very few neutrophils (**FIGURE 2**). No acantholytic keratinocytes suggestive of pemphigus foliaceus or microorganisms (e.g., cocci, rods) were observed.

The patient was sedated with intravenous medetomidine, and an injection of 0.5 mL of lidocaine
hydrochloride 2% was administered subcutaneously to provide additional local anesthesia. Two 6-mm punch biopsy samples were obtained from the skin lesions. Samples from the eroded/ulcerated plaques featured extensive epidermal ulceration, edema, and marked dermal inflammation characterized by large numbers of eosinophils, scattered neutrophils, and few macrophages that infiltrated and surrounded the hair follicles (FIGURE 3A AND 3B). An occasional follicular rupture (furunculosis) with free dermal hair shafts was observed (FIGURE 3B). In some areas, a multifocal aggregate of degenerated eosinophils and neutrophils surrounded hypereosinophilic, shrunken, and fragmented collagen fibers (“flame figures”; FIGURE 3C). Special stains (Gram, Giemsa, periodic acid–Schiff) did not reveal any microorganisms.

The history of peracute development, clinical features (e.g., lesion localization, cytology findings showing numerous eosinophils and no bacteria) and histopathologic findings were consistent with canine folliculitis/furunculosis.

TREATMENT AND FOLLOW-UP
Amoxicillin–clavulanic acid was discontinued. Oral prednisone was started at 1 mg/kg q24h for 10 days, and the dose was progressively tapered and stopped over a total course of 24 days. After 1 week of treatment, the owner reported significant improvement in clinical signs without any other complaints (FIGURE 4). At the time of this writing, the dog’s skin lesions have been maintained in clinical remission for more than 5 months and no recurrences have been observed.

DISCUSSION
Some dermatologic conditions, such as sterile eosinophilic dermatoses, can cause severe cutaneous signs with progressive worsening and may have serious systemic consequences. A lack of familiarity with these conditions may delay diagnosis and appropriate treatment. In this patient, the history of fulminant progressive development; presence of erythematous, eroded to ulcerated plaques localized to the nasal bridge; cytologic findings of numerous eosinophils without any microorganisms; and histopathologic findings of sterile eosinophilic folliculitis and furunculosis supported the diagnosis of canine eosinophilic folliculitis/furunculosis.

Canine eosinophilic folliculitis/furunculosis is an uncommon skin disease that predominantly affects young large-breed dogs aged between 2 and 5 years; no sex predilections have been reported. Most reported patients had abundant access to the outdoors, like public gardens and parks. The exact pathogenesis remains unknown, but the histopathologic findings and the pattern/localization of lesions suggest a reaction to insect bites and arthropods.

In a “typical” insect bite–induced type I hypersensitivity reaction, skin lesions show a tendency
to slowly resolve a few hours to days after the initial exposure. In contrast, skin lesions of canine eosinophilic folliculitis/furunculosis generally show a progressive worsening after the initial development. The nasal bridge is the affected site predominantly described in cases of canine eosinophilic folliculitis/furunculosis; other sites, such as the periocular area, pinnae, thorax, and limbs, have been affected in some patients.\(^1\)\(^,\)\(^2\)\(^,\)\(^5\)\(^-\)\(^9\)

Papules, plaques, and nodules that rapidly fistulate and drain serosanguinous exudate are characteristic of canine eosinophilic folliculitis/furunculosis.\(^1\)\(^,\)\(^2\)\(^,\)\(^5\)\(^-\)\(^9\) Severely affected dogs may be febrile, lethargic, and anorectic, whereas pruritus and pain are variable.\(^1\)\(^,\)\(^2\)\(^,\)\(^5\)\(^-\)\(^9\) The history, type, and localization of skin lesions in the dog in this case closely resembled those uniquely described in canine eosinophilic folliculitis/furunculosis.

Canine eosinophilic folliculitis/furunculosis is diagnosed based on history, characteristic clinical signs, cytology, and skin biopsies.\(^1\)\(^,\)\(^2\)\(^,\)\(^5\)\(^-\)\(^9\) Cyto logic examination of impression smears commonly reveals numerous eosinophils, whereas in long-standing (e.g., lasting more than 10 days) progressive and ulcerated skin lesions, secondary infection with degenerate neutrophils and intracellular bacteria may sometimes be observed.\(^1\)\(^,\)\(^2\)\(^,\)\(^5\)\(^-\)\(^9\) This secondary infection is likely a consequence of skin barrier impairment by epidermal ulceration and the progression of skin lesions over time. Histopathology typically shows eosinophilic folliculitis and furunculosis; occasionally, there may be a mixed inflammatory infiltrate with dermal hemorrhage and collagen degeneration.\(^2\) The epidermis is typically ulcerated with a marked dermal and cutaneous mucinosis, and flame figures are often observed.\(^2\) In the present case, skin cytology revealed numerous eosinophils and histopathologic examination showed eosinophilic folliculitis and furunculosis with flame figures. No microorganisms were found on the cytologic and histopathologic examination; however, the patient was also provided with systemic antibiotics before diagnostic samples were obtained.

Textbooks list several clinical diagnostic differentials for canine eosinophilic folliculitis/furunculosis, such as staphylococcal nasal folliculitis/furunculosis, demodicosis, thermal burn, dermatophytosis, juvenile cellulitis, and drug eruptions (e.g., Stevens-Johnson syndrome/toxic epidermal necrolysis [SJS/TEN]).\(^2\) Juvenile cellulitis commonly manifests in puppies between 5 weeks and 6 months of age, with papular, pustular, nodular, and alopecic skin lesions and draining tracts most prevalent on the lips, muzzle, and eyelids.\(^10\) Cytologic and histopathologic examination in juvenile cellulitis reveal “sterile” pyogranulomatous inflammation.\(^10\) Despite the potential similarity in clinical signs of juvenile cellulitis and canine eosinophilic folliculitis/furunculosis, the cytologic and histopathologic findings in this case, as well as the age of onset, did not support the diagnosis of juvenile cellulitis. Staphylococcal nasal folliculitis/furunculosis, sometimes called “nasal pyoderma,” is primarily characterized by a neutrophilic inflammatory cell infiltrate with numerous bacteria but few eosinophils;\(^11\) bacteria were absent and numerous eosinophils were observed on cytology in this dog. Drug hypersensitivities/eruptions such as SJS/TEN were deemed less likely, as diffuse erythematous or purpuric rash with only epidermal erosions was not present and mucocutaneous junctions were not involved.\(^12\)

Oral glucocorticoids have been the mainstay of therapy for canine eosinophilic folliculitis/furunculosis; dosages for prednisone/prednisolone from 1 to 2 mg/kg have been recommended.\(^1\)\(^,\)\(^2\)\(^,\)\(^5\)\(^-\)\(^9\) In the present case, remission of skin lesions followed the implementation of short-term, slowly tapered prednisone initiated at 1 mg/kg q24h. Antimicrobial therapy should be instituted if a secondary infection is observed on cytology and/or bacterial culture.

**SUMMARY**

The case described in this report emphasizes the importance of an accurate diagnosis of canine eosinophilic folliculitis/furunculosis as well as early and adequate treatment to promote a satisfactory response. Patients with canine eosinophilic folliculitis/furunculosis may present on an emergency basis, and lack of familiarity with this disease may delay diagnosis and appropriate treatment. **TVP**
References


KBroVet™-CA1 (potassium bromide chewable tablets) For complete prescribing information, see full package insert. Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian. It is a violation of Federal Law to use this product other than as directed in the labeling. Indication: for the control of seizures associated with idiopathic epilepsy in dogs. Warnings: Not for human use. Keep out of reach of children. Contact a physician in case of accidental ingestion by humans. KBroVet™-CA1 should not be used in animals with a history of hypersensitivity to bromide or any of the components of the tablets. Not for use in cats. Keep tablets in a secured location out of reach of dogs, cats, and other animals to prevent accidental ingestion or overdose. Precautions: The safe use of KBroVet™-CA1 Chewable Tablets has not been evaluated in dogs that are intended for breeding, that are pregnant or lactating, or less than 6 months of age. Reproductive effects of potassium bromide (KBr) have been reported in other species. In dogs, ataxia, diarrhea, hematochezia, excessive salivation, shivering, skin lesions, stupor progressing to coma, and death have been reported with high doses.1,2 Dogs receiving KBroVet™-CA1 should be carefully monitored when changing diets, administering chloride-containing IV fluids, and administering concurrent medications. Careful monitoring is important in dogs that have a condition that may cause difficulty maintaining electrolyte balance. Animals with decreased renal function may be predisposed to bromide toxicity. Some dogs may experience epileptic episodes that are unresponsive or refractory to KBr monotherapy and KBr alone may not be adequate treatment for every dog with idiopathic epilepsy. Adverse Reactions: In a retrospective field study of 51 dogs diagnosed with idiopathic epilepsy and treated with KBr, the most common clinical abnormalities documented in the 60 day period after start of KBr therapy were increased appetite, weight gain, vomiting/regurgitation and sedation. Additional field reports of clinical abnormalities in dogs dosed with KBr for idiopathic epilepsy showed polyphagia, polyuria, polydipsia, weight gain, lethargy and decreased physical activity. Ataxia was the most common body-system (i.e. CNS) specific clinical finding. Adverse events associated with concurrent use of KBr with other antiepileptic drugs such as phenobarbital have been reported, including sedation, irritability, restlessness, depression, behavioral changes, ataxia, hind limb paresis, mydriasis, stupor, and coma. These neurologic signs were reported to be reversible.3 Reasonable Expectation of Effectiveness: This drug is conditionally approved pending a full demonstration of effectiveness. In a dose determination retrospective study involving a total of 284 canine case records, the mean total oral dose was determined to be 46.6 (±21.9) mg/kg/day with a range of 24.5-68.3 mg/kg/day, describing the range to achieve serum bromide concentrations within 10% of the published therapeutic range for dogs with idiopathic epilepsy. In a pilot retrospective study spanning a 5.7 year period, involving the review of case records of 51 client-owned dogs contributed by 18 veterinarians, and comparing the 30 day period before initial treatment with KBr and the 30 day period of steady state KBr dosing, 27 cases were determined as valid for evaluation of effectiveness. The mean maintenance dose in those 27 cases was 37 mg/kg/day, with a mean duration of 286 days. Approximately 67% of those cases were dosed once daily and 33% were dosed twice daily. Based on seizure count results, 70% of the 27 cases were defined as “success” and 30% were defined as “failures.” Based on seizure event day results, 67% were defined as “success” and 33% were defined as “failures.” Seizure severity score decreased or did not change in 25 of the 27 cases evaluated for effectiveness. Overall, of the 27 dogs included in the effectiveness analysis, 67% were considered treatment successes and 33% were considered treatment failures. To obtain full product information please call 800-874-9764 or visit KBroVet.com.

Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-544. Pegasus Laboratories, Inc.

Dosage and Administration: For use in dogs only. The total recommended daily dosage range for KBroVet Chewable Tablets is 23-68 mg/kg, dosed with or without food, and should be adjusted based on monitoring of clinical response of the individual patient.1 Use of an initial loading regimen may be considered on an individual patient basis, balancing the time required to achieve a therapeutic response while minimizing side effects. Storage: Store at 20-25°C (68-77°F). WARNINGS: NOT FOR USE IN HUMANS. KEEP THIS AND ALL DRUGS OUT OF REACH OF CHILDREN.


Frane Banovic
Dr. Banovic graduated from veterinary school in Zagreb, Croatia, and received his PhD in veterinary microbiology from the University of Zagreb. He finished a 1-year rotational internship at the Veterinary School in Munich, Germany, before completing a 3-year dermatology residency at North Carolina State University; afterward, he enrolled in a postdoctoral fellowship in investigative dermatology with a primary research focus on itch in atopic dermatitis and staphylococcal pyoderma. Dr. Banovic favors interdisciplinary approaches to biologic questions and incorporates basic immunology as well as cell biology and biochemical approaches in his research. He is presently an associate professor of dermatology at the University of Georgia College of Veterinary Medicine.